S&P 500   3,320.79 (-0.27%)
DOW   29,196.04 (-0.52%)
QQQ   223.28 (-0.04%)
AAPL   316.57 (-0.68%)
FB   221.44 (-0.32%)
MSFT   166.50 (-0.36%)
GOOGL   1,482.25 (+0.18%)
AMZN   1,892.00 (+1.46%)
CGC   24.15 (-2.97%)
NVDA   247.94 (-0.54%)
BABA   222.26 (-2.27%)
MU   58.97 (+2.27%)
GE   11.66 (-1.27%)
TSLA   547.20 (+7.19%)
AMD   51.05 (+0.24%)
T   38.52 (+0.36%)
ACB   2.01 (-5.63%)
F   9.21 (+0.55%)
NFLX   338.11 (-0.46%)
PRI   126.41 (-1.57%)
BAC   34.26 (-1.30%)
DIS   143.56 (-0.53%)
GILD   62.63 (-0.56%)
S&P 500   3,320.79 (-0.27%)
DOW   29,196.04 (-0.52%)
QQQ   223.28 (-0.04%)
AAPL   316.57 (-0.68%)
FB   221.44 (-0.32%)
MSFT   166.50 (-0.36%)
GOOGL   1,482.25 (+0.18%)
AMZN   1,892.00 (+1.46%)
CGC   24.15 (-2.97%)
NVDA   247.94 (-0.54%)
BABA   222.26 (-2.27%)
MU   58.97 (+2.27%)
GE   11.66 (-1.27%)
TSLA   547.20 (+7.19%)
AMD   51.05 (+0.24%)
T   38.52 (+0.36%)
ACB   2.01 (-5.63%)
F   9.21 (+0.55%)
NFLX   338.11 (-0.46%)
PRI   126.41 (-1.57%)
BAC   34.26 (-1.30%)
DIS   143.56 (-0.53%)
GILD   62.63 (-0.56%)
S&P 500   3,320.79 (-0.27%)
DOW   29,196.04 (-0.52%)
QQQ   223.28 (-0.04%)
AAPL   316.57 (-0.68%)
FB   221.44 (-0.32%)
MSFT   166.50 (-0.36%)
GOOGL   1,482.25 (+0.18%)
AMZN   1,892.00 (+1.46%)
CGC   24.15 (-2.97%)
NVDA   247.94 (-0.54%)
BABA   222.26 (-2.27%)
MU   58.97 (+2.27%)
GE   11.66 (-1.27%)
TSLA   547.20 (+7.19%)
AMD   51.05 (+0.24%)
T   38.52 (+0.36%)
ACB   2.01 (-5.63%)
F   9.21 (+0.55%)
NFLX   338.11 (-0.46%)
PRI   126.41 (-1.57%)
BAC   34.26 (-1.30%)
DIS   143.56 (-0.53%)
GILD   62.63 (-0.56%)
S&P 500   3,320.79 (-0.27%)
DOW   29,196.04 (-0.52%)
QQQ   223.28 (-0.04%)
AAPL   316.57 (-0.68%)
FB   221.44 (-0.32%)
MSFT   166.50 (-0.36%)
GOOGL   1,482.25 (+0.18%)
AMZN   1,892.00 (+1.46%)
CGC   24.15 (-2.97%)
NVDA   247.94 (-0.54%)
BABA   222.26 (-2.27%)
MU   58.97 (+2.27%)
GE   11.66 (-1.27%)
TSLA   547.20 (+7.19%)
AMD   51.05 (+0.24%)
T   38.52 (+0.36%)
ACB   2.01 (-5.63%)
F   9.21 (+0.55%)
NFLX   338.11 (-0.46%)
PRI   126.41 (-1.57%)
BAC   34.26 (-1.30%)
DIS   143.56 (-0.53%)
GILD   62.63 (-0.56%)
Log in
(Ad)
What if you could buy one tiny stock today for $10 - at the center of a growing tech industry - that experts believe will explode a massive 77,400%? Wall Street legend Paul Mampilly recently identified this as the stock of the century. Buying up a handful of shares of this small company now could change your life and even make you millions.

NYSE:QGEN - Qiagen Stock Price, Forecast & News

$35.66
-0.10 (-0.28 %)
(As of 01/21/2020 04:00 PM ET)
Today's Range
$35.56
Now: $35.66
$36.22
50-Day Range
$30.25
MA: $37.41
$42.60
52-Week Range
$25.04
Now: $35.66
$43.16
Volume2.80 million shs
Average Volume2.82 million shs
Market Capitalization$8.04 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.91
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone31-77-355-6600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.50 billion
Cash Flow$2.45 per share
Book Value$11.69 per share

Profitability

Net Income$190.38 million

Miscellaneous

Employees4,952
Market Cap$8.04 billion
Next Earnings Date2/4/2020 (Confirmed)
OptionableOptionable

Receive QGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for QGEN and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

Billions of dollars are pouring into one long-ignored asset Goldman Sachs expects will soar in the first quarter of 2020. Go here to see hard-asset expert's #1 way to play this massive shift before it turns into a runaway train.

Qiagen (NYSE:QGEN) Frequently Asked Questions

What is Qiagen's stock symbol?

Qiagen trades on the New York Stock Exchange (NYSE) under the ticker symbol "QGEN."

How were Qiagen's earnings last quarter?

Qiagen NV (NYSE:QGEN) posted its quarterly earnings data on Wednesday, October, 30th. The company reported $0.36 EPS for the quarter, beating the Zacks' consensus estimate of $0.35 by $0.01. The business earned $382.70 million during the quarter, compared to analysts' expectations of $382.98 million. Qiagen had a positive return on equity of 12.24% and a negative net margin of 1.68%. The business's revenue was up 1.3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.35 earnings per share. View Qiagen's Earnings History.

When is Qiagen's next earnings date?

Qiagen is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for Qiagen.

How can I listen to Qiagen's earnings call?

Qiagen will be holding an earnings conference call on Tuesday, February 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Qiagen issued on next quarter's earnings?

Qiagen updated its FY19 earnings guidance on Wednesday, October, 30th. The company provided earnings per share (EPS) guidance of $1.43-1.44 for the period, compared to the Thomson Reuters consensus estimate of $1.38. The company issued revenue guidance of ~$1.56 billion, compared to the consensus revenue estimate of $1.53 billion.

What price target have analysts set for QGEN?

19 equities research analysts have issued 12-month target prices for Qiagen's stock. Their forecasts range from $28.00 to $48.00. On average, they anticipate Qiagen's stock price to reach $35.90 in the next year. This suggests a possible upside of 0.7% from the stock's current price. View Analyst Price Targets for Qiagen.

What is the consensus analysts' recommendation for Qiagen?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Qiagen in the last year. There are currently 1 sell rating, 11 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Qiagen.

Has Qiagen been receiving favorable news coverage?

Media stories about QGEN stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Qiagen earned a daily sentiment score of 2.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Qiagen.

Are investors shorting Qiagen?

Qiagen saw a decline in short interest in December. As of December 31st, there was short interest totalling 4,490,000 shares, a decline of 20.4% from the December 15th total of 5,640,000 shares. Based on an average daily trading volume, of 2,820,000 shares, the days-to-cover ratio is presently 1.6 days. Approximately 2.1% of the shares of the stock are sold short. View Qiagen's Current Options Chain.

Who are some of Qiagen's key competitors?

What other stocks do shareholders of Qiagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Qiagen investors own include Netflix (NFLX), Gilead Sciences (GILD), NVIDIA (NVDA), Boeing (BA), QUALCOMM (QCOM), Pfizer (PFE), Twitter (TWTR), Cisco Systems (CSCO), Verizon Communications (VZ) and Exxon Mobil (XOM).

Who are Qiagen's key executives?

Qiagen's management team includes the folowing people:
  • Mr. Peer Michael Schatz, CEO, MD & Member of Management Board (Age 53)
  • Dr. Roland Sackers, CFO, MD & Member of Management Board (Age 50)
  • Dr. Barthold Piening, Sr. VP & Head of Global Operations (Age 61)
  • Mr. John Gilardi, VP of Corp. Communications & Investor Relations
  • Mr. Jean-Pascal Viola, Head of Corp. Bus. Devel., Intellectual Property & Litigation and Sr. VP

Who are Qiagen's major shareholders?

Qiagen's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Manning & Napier Group LLC (0.28%), Assenagon Asset Management S.A. (0.02%), Nisa Investment Advisors LLC (0.02%), Advisors Capital Management LLC (0.01%), Alpine Global Management LLC (0.00%) and Huntington National Bank (0.00%).

Which major investors are selling Qiagen stock?

QGEN stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, Assenagon Asset Management S.A. and Nisa Investment Advisors LLC.

Which major investors are buying Qiagen stock?

QGEN stock was bought by a variety of institutional investors in the last quarter, including Alpine Global Management LLC, Advisors Capital Management LLC and Huntington National Bank.

How do I buy shares of Qiagen?

Shares of QGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Qiagen's stock price today?

One share of QGEN stock can currently be purchased for approximately $35.66.

How big of a company is Qiagen?

Qiagen has a market capitalization of $8.04 billion and generates $1.50 billion in revenue each year. The company earns $190.38 million in net income (profit) each year or $1.34 on an earnings per share basis. Qiagen employs 4,952 workers across the globe.View Additional Information About Qiagen.

What is Qiagen's official website?

The official website for Qiagen is http://www.qiagen.com/.

How can I contact Qiagen?

Qiagen's mailing address is HULSTERWEG 82, VENLO P7, 5912 PL. The company can be reached via phone at 31-77-355-6600 or via email at [email protected]


MarketBeat Community Rating for Qiagen (NYSE QGEN)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  199 (Vote Outperform)
Underperform Votes:  229 (Vote Underperform)
Total Votes:  428
MarketBeat's community ratings are surveys of what our community members think about Qiagen and other stocks. Vote "Outperform" if you believe QGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel